2025 ESsCD Guidelines: Updates in adult coeliac disease diagnosis

November 2025

The European Society for the Study of Coeliac Disease (ESsCD) released updated 2025 guidelines on diagnosing coeliac disease (CeD) in adults in September 2025. The changes recommended in this update aim to improve diagnostic accuracy, reduce unnecessary procedures, and ensure patient-centered care. 

Key updates for clinical practice

1. Refined serology strategy

  • IgA anti-tissue transglutaminase 2 (TG2) ELISA-based assays remains the first-line test, and total IgA must be measured in parallel.
  • In case of IgA deficiency, the use IgG-based assays (anti-TG2, anti-deamidated gliadin protein (DGP)) is advised.
  • Routine anti-endomysial antibody (EMA) testing is no longer advised and is reserved for ambiguous cases (e.g., other autoimmune or liver diseases) before proceeding with a duodenal biopsy.
  • Stool and saliva tests are discouraged due to poor performance.
  • Point-of-care tests: positive results must be confirmed with formal serology and/or biopsy.

2. Conditional no-biopsy approach

  • Adults younger than 45 years with IgA anti-TG2 titer ≥10× upper limit of normal (ULN), confirmed on a second sample, may be diagnosed without duodenal biopsy.
  • This pathway is not recommended if red flag symptoms are present (e.g., bleeding, dysphagia, obstruction).
  • Requires shared decision-making and specialist oversight.

3. Standardised biopsy protocol

  • The reference stays to take at least 4 biopsies from the second duodenum plus 2 from the bulb, and the modified Marsh classification remains reference.
  • Marsh I biopsy scoring with negative serology indicates that coeliac disease is unlikely; other causes should be investigated.

4. Guidance for complex scenarios

  • Potential CeD: positive serology, normal histology → classify as potential if HLA-DQ2/DQ8 positive.
  • Seronegative villous atrophy: after exclusion of other causes, rely on gluten free diet (GFD) response in HLA-DQ2/8 positive individuals.
  • Already on GFD: gluten challenge recommended (≥3 g/day for 6 weeks, biopsy endpoint).

5. HLA typing

  • Not routine but useful in uncertain cases (e.g., gluten challenge, seronegative villous atrophy, potential CeD, or prior GFD).
  • Negative results rule out CeD.

6. Other

  • Non-coeliac wheat sensitivity (NCWS): consider if reproducible gluten-related symptoms but negative CeD serology and wheat allergy tests.

What is the clinical impact of the updated 2025 ESsCD guidelines?

  • Streamlines diagnostic algorithms while maintaining high accuracy.
  • Aligns adult practice closer to pediatric no-biopsy pathways, with safeguards.
  • Supports precision in histology and serology use, reducing misdiagnosis.
  • Promotes shared decision-making with patients regarding invasive procedures and gluten challenge.

Bottom line

These ESsCD 2025 guidelines emphasize validated serology, stricter biopsy standards, selective use of genetics, and a conditional no-biopsy pathway — all designed to improve diagnostic certainty while minimizing unnecessary interventions.

Find out more here: https://pubmed.ncbi.nlm.nih.gov/40999951/

Anti TG2: Anti Tissue Transglutaminase 2

Anti DGP: Anti Deamidated Gliadin Peptide

Anti EMA testing: Anti Endomysial Antibodies testing